Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 45

2.

The role of phytosterols in the pathogenesis of liver complications of pediatric parenteral nutrition.

Clayton PT, Whitfield P, Iyer K.

Nutrition. 1998 Jan;14(1):158-64. Review.

PMID:
9437703
3.

Phytosterols, Lipid Administration, and Liver Disease During Parenteral Nutrition.

Zaloga GP.

JPEN J Parenter Enteral Nutr. 2015 Sep;39(1 Suppl):39S-60S. doi: 10.1177/0148607115595978. Review.

PMID:
26177665
4.

Fish oil containing intravenous lipid emulsions in parenteral nutrition-associated cholestatic liver disease.

Koletzko B, Goulet O.

Curr Opin Clin Nutr Metab Care. 2010 May;13(3):321-6. doi: 10.1097/MCO.0b013e3283385407. Review.

PMID:
20393276
5.

Pathogenesis and treatment of parenteral nutrition-associated liver disease.

Xu ZW, Li YS.

Hepatobiliary Pancreat Dis Int. 2012 Dec 15;11(6):586-93. Review.

6.

Mechanisms of disease: update on the molecular etiology and fundamentals of parenteral nutrition associated cholestasis.

Carter BA, Shulman RJ.

Nat Clin Pract Gastroenterol Hepatol. 2007 May;4(5):277-87. Review.

PMID:
17476210
7.

Treatment of parenteral nutrition-associated liver disease: the role of lipid emulsions.

Nandivada P, Carlson SJ, Chang MI, Cowan E, Gura KM, Puder M.

Adv Nutr. 2013 Nov 6;4(6):711-7. doi: 10.3945/an.113.004770. Review.

8.

Prevention of parenteral nutrition-associated liver disease: lipid minimization.

Cober MP, Teitelbaum DH.

Curr Opin Organ Transplant. 2010 Jun;15(3):330-3. doi: 10.1097/MOT.0b013e328338c2da. Review.

PMID:
20386446
9.

Genetic cholestasis, causes and consequences for hepatobiliary transport.

Jansen PL, Sturm E.

Liver Int. 2003 Oct;23(5):315-22. Review.

PMID:
14708891
10.

Isolated liver transplantation in pediatric short bowel syndrome: is there a role?

Diamond IR, Wales PW, Grant DR, Fecteau A.

J Pediatr Surg. 2006 May;41(5):955-9. Review.

PMID:
16677892
11.

Parenteral nutrition-associated cholestasis: an American Pediatric Surgical Association Outcomes and Clinical Trials Committee systematic review.

Rangel SJ, Calkins CM, Cowles RA, Barnhart DC, Huang EY, Abdullah F, Arca MJ, Teitelbaum DH; 2011 American Pediatric Surgical Association Outcomes and Clinical Trials Committee..

J Pediatr Surg. 2012 Jan;47(1):225-40. doi: 10.1016/j.jpedsurg.2011.10.007. Review.

PMID:
22244423
12.

Ursodiol in patients with parenteral nutrition-associated cholestasis.

San Luis VA, Btaiche IF.

Ann Pharmacother. 2007 Nov;41(11):1867-72. Review.

PMID:
17911205
13.

Final report of the amended safety assessment of PEG-5, -10, -16, -25, -30, and -40 soy sterol.

[No authors listed]

Int J Toxicol. 2004;23 Suppl 2:23-47. Review.

PMID:
15513823
14.

Cholestatic liver diseases: slow progress in understanding and treating slowly progressive disorders.

Vleggaar FP, Van Ooteghem NA, Van Buuren HR, Van Berge Henegouwen GP.

Scand J Gastroenterol Suppl. 2000;(232):86-92. Review.

PMID:
11232499
15.

[Hepatic complications in parenteral nutrition].

Müller MJ.

Z Gastroenterol. 1996 Jan;34(1):36-40. Review. German.

PMID:
8776174
16.

[Bile acids in the process of canalicular bile formation].

Sinel'nik TB, Sinel'nik OD, Ribal'chenko VK.

Fiziol Zh. 2003;49(6):80-93. Review. Ukrainian.

PMID:
14965044
17.

Mechanisms of cholestasis.

Kullak-Ublick GA, Meier PJ.

Clin Liver Dis. 2000 May;4(2):357-85. Review.

PMID:
11232196
18.
19.

The role of sterols in lipid emulsions for parenteral nutrition.

Saubion JL, Hazane C, Jalabert M.

Nutrition. 1998 May;14(5):477-8. Review. No abstract available.

PMID:
9614320
20.

Mitochondrially-mediated toxicity of bile acids.

Palmeira CM, Rolo AP.

Toxicology. 2004 Oct 15;203(1-3):1-15. Review.

PMID:
15363577
Items per page

Supplemental Content

Support Center